[go: up one dir, main page]

EP0000533A1 - N-Substituted 9,10-dihydrolysergic acid esters and a method for their preparation - Google Patents

N-Substituted 9,10-dihydrolysergic acid esters and a method for their preparation Download PDF

Info

Publication number
EP0000533A1
EP0000533A1 EP78100419A EP78100419A EP0000533A1 EP 0000533 A1 EP0000533 A1 EP 0000533A1 EP 78100419 A EP78100419 A EP 78100419A EP 78100419 A EP78100419 A EP 78100419A EP 0000533 A1 EP0000533 A1 EP 0000533A1
Authority
EP
European Patent Office
Prior art keywords
hydrogen
atoms
compound
general formula
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP78100419A
Other languages
German (de)
French (fr)
Other versions
EP0000533B1 (en
Inventor
Rudolf Rucman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lek Pharmaceuticals dd
Original Assignee
Lek Pharmaceuticals and Chemical Co dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals and Chemical Co dd filed Critical Lek Pharmaceuticals and Chemical Co dd
Publication of EP0000533A1 publication Critical patent/EP0000533A1/en
Application granted granted Critical
Publication of EP0000533B1 publication Critical patent/EP0000533B1/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D457/00Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8

Definitions

  • the present invention relates to N-substituted 9,10-dihydrolysergic acid esters and a process for their preparation.
  • the alkyl group is simultaneously introduced into the 1-position of the compound of the general formula II and the group in the 8-position is esterified by the same alkyl group which was introduced into the 1-position.
  • R denotes hydrogen or an organic radical which can be hydrolyzed in an alkaline medium.
  • 9,10-dihydrplysergic acid esters can also be used for the process according to the invention, in which R denotes any organic radical which is higher than the introduced group R 1 is.
  • This organic radical R is replaced by a lower group R 1 by the intermediate alkaline hydrolysis.
  • the starting materials of formula II are alkylated by compounds of general formula III in the presence of a phase transfer catalyst.
  • This catalyst is an ammonium or phosphonium compound of the general formula Z 4 QA, where Z is the same or different alkyl, cycloalkyl, aryl, arylalkyl or alkylaryl groups with 1-16 C atoms, Q is a quaternary nitrogen or phosphorus atom and A is an anion such as chloride, bromide, iodide, hydrogen sulfate, acetate, tosylate, etc.
  • tetrabutylammonium bromide tetrabutylammonium hydrogen sulfate
  • triethylbenzylammonium chloride tricaprylylmethylammonium chloride
  • tetrabutylphosphonium bromide etc.
  • the phase transfer catalyst is used in an amount of 0.1 to 3 moles to 1 mole of 9,10-dihydroloysergic acid.
  • the amount of the catalyst within these limits has a great influence on the reaction rate. Since 9,10-dihydrolysergic acid and its derivatives are very sensitive compounds, a rapid course of the reaction is desirable. Therefore, the use of the catalyst in an amount close to the above upper limit is advantageous.
  • the water-immiscible inert organic solvent can e.g. Benzene, Toluok, xylene or a saturated hydrocarbon such as pentane, hexane, heptane or cyclohexane.
  • the alkaline aqueous phase is a 20-50% aqueous alkali hydroxide solution, e.g. Sodium hydroxide solution.
  • the inventive method is carried out at room temperature or moderately elevated temperature.
  • the substitution of the 9,10-dihydrolysergic acids in the 8-position is faster than in the 1-position. Therefore, the esters and the N-substituted esters can be isolated from the reaction mixture at the beginning of the reaction. By continuing the reaction, the concentration of the ester is reduced until it completely disappears at the end of the reaction and only the N-substituted ester is obtained.
  • the compounds according to the invention are important intermediate compounds for the synthesis of therapeutically highly effective compounds with N-substituted groups in the 1-position.
  • the further reactions of the synthesis proceed primarily in the direction of the reduction of the ester group in the 8-position to a primary alcohol group, to which a suitable acid residue, for example 5-bromnicotinic acid, is then bound. Therefore, the simultaneous introduction of the group R 1 in the 1 position and esterification of the carboxy group in the 8 position, which is thereby more accessible for the reduction into the alcohol group, is very advantageous.
  • the toluene phase is separated from the water phase and the water phase was extracted 3 times with 200 ml of toluene and 1.66 g (13.22 mmol) of dimethyl sulfate, in each case 20 minutes intensively stirred at 30 ° C.
  • the toluene extract is separated from the aqueous solution and then the aqueous solution is extracted twice with 200 ml of toluene and 0.63 g (5 mmol) of dimethyl sulfate.
  • the combined toluene extracts are washed with water and evaporated to dryness in vacuo. There are 2.14 g or 71.8% of theory.
  • Theor. obtained crystalline 1-methyl-9,10-dihydrolysergic acid methyl ester.
  • the compound has the properties given in Example 1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

N-Substituierte 9,10-Dihydrolysergsäureester der Formel <IMAGE> worin R1 Alkylrests mit 1-5 C-Atomen, Alkenylreste mit 2-5 C-Atomen oder Cycloalkylreste mit 3-5 C-Atomen, R2 Wasserstoff oder Alkoxyreste mit 1-3 C-Atomen und X Wasserstoff oder Halogen bedeuten, wobei die Verbindung, worin R1 Methyl- oder Äthylreste und R2 und X Wasserstoff bedeuten, sowie die Verbindung worin R1 einen Methylrest, R2 einen Methoxyrest und X Wasserstoff bedeuten, ausgenommen sind, als Zwischenverbindugen für die Synthese von therapeutisch hochwirksamen Verbindungen sowie Verfahren zu ihrer Herstellung durch Umsetzung von gegebenenfalls veresterten 9,10-Dihydrolylsergsäuren der allgemeinen Formel <IMAGE> worin R Wasserstoff oder einen in alkalischen Medium hydrolisierbaren organischen Rest bedeutet und X und R2 die vorstehend angegebenen Bedeutungen besitzen, mit einer Verbindung der allgemeinen Formel R1Y (III) worin R1 die unter der Formel I angegebene Bedeutung hat und Y Halogen oder Sulfat bedeutet, in Anwesenheit eines Katalysators zur Phasenübertragung, eines mit Wasser nicht mischbaren inerten organischen Lösungsmittels ind einer alkalischen wässrigen Phase. Diese Verfahren zeichnet sich gegenüber bekannten Verfahren durch eine gute Selektivität, einen einfachen und schellen Reaktionsverlauf, wobei die Reaktion leicht kontrolliert werden kann, die Verwendung von üblichen Lösungsmittel, aus denen das Wasser nicht entfernt werden braucht, sowie vorallem durch Reaktionsbedingungen aus, die ein gefahrloses Arbeiten ermöglichen. Die Verbindungen sind wichtige Zwischenverbindungen zur Synthese von therapeutische hochwirksamen Verbindungen mit N-substituierter Gruppe in der 1-Stellung.N-substituted 9,10-dihydrolysergic esters of the formula <IMAGE> in which R1 is alkyl with 1-5 C atoms, alkenyl with 2-5 C atoms or cycloalkyl with 3-5 C atoms, R2 is hydrogen or alkoxy with 1-3 C atoms and X are hydrogen or halogen, the compound in which R1 is methyl or ethyl and R2 and X are hydrogen, and the compound in which R1 is a methyl radical, R2 is a methoxy radical and X is hydrogen, except as intermediates for the Synthesis of therapeutically highly effective compounds and processes for their preparation by reacting optionally esterified 9,10-dihydrolylsergic acids of the general formula <IMAGE> in which R is hydrogen or an organic radical which can be hydrolyzed in alkaline medium and X and R2 have the meanings indicated above, with a Compound of the general formula R1Y (III) in which R1 has the meaning given under the formula I and Y is halogen or sulfate, in Presence of a phase transfer catalyst, an inert organic solvent immiscible with water and an alkaline aqueous phase. Compared to known processes, this process is distinguished by good selectivity, a simple and rapid course of the reaction, the reaction being easy to control, the use of customary solvents from which the water does not need to be removed, and, above all, by reaction conditions which are safe Enable work. The compounds are important intermediates for the synthesis of therapeutic, highly effective compounds with an N-substituted group in the 1-position.

Description

Die vorliegende Erfindung betrifft N-substituierte 9,10-Dihydrolysergsäureester sowie ein Verfahren zu deren Herstellung.The present invention relates to N-substituted 9,10-dihydrolysergic acid esters and a process for their preparation.

Neue erfindungsgemäße N-substituierte 9,10-Dihydrolysergsäureester der allgemeinen Formel

Figure imgb0001
worin

  • R1 Alkylreste mit 1-5 C-Atomen, Alkenylreste mit 2-5 C-Atomen oder Cycloalkylreste mit 3-5 C-Atomen;
  • R2 Wasserstoff oder Alkoxyreste mit 1-3 C-Atomen und
  • X Wasserstoff oder Halogen bedeuten,

wobei die Verbindung, worin R1 Methyl- oder Äthylresteund R2 und X Wasscrstoff bedeuten, sowie die Verbindung, worin R1 einen Methylrest, R2 einen Methoxyrest und X Wasserstoff bedeuten, ausgenommen sind,
sind wichtige Zwischenverbindungen für die Synthese von therapeutisch hochwirksamen Verbindungen.New N-substituted 9,10-dihydrolysergic esters of the general formula according to the invention
Figure imgb0001
wherein
  • R 1 alkyl radicals with 1-5 C atoms, alkenyl radicals with 2-5 C atoms or cycloalkyl radicals with 3-5 C atoms;
  • R 2 is hydrogen or alkoxy radicals with 1-3 C atoms and
  • X is hydrogen or halogen,

with the exception of the compound in which R 1 is methyl or ethyl and R 2 and X are hydrogen, and the compound in which R 1 is methyl, R 2 is methoxy and X is hydrogen,
are important intermediates for the synthesis of therapeutically highly effective compounds.

Das bisher bekannte Verfahren der N-Alkylierung von Lysergsäuren oder anderen Verbindungen dieser Basisstruktur beruht auf der Metallisierung von Indolstickstoff mit Kalium oder Lithium in flüssigem Ammoniak bei -50°C und anschliessender Einführung der Alkylgruppe. Gemäß diesem Verfahren wird die Alkylgruppe nur in die 1-Stelluna eingeführt, Da die Reaktion niaht Lesonders selektiv ist, wird sie, insbesondere beim notwendigen Überschuss von Alkylhalogenid, auch durch die Substitution des aktivierten Wasserstoffs am Chiralitätszentrum 8 mit einer Alkylgruppe begleitet, so dass die Ausbeute an N-Alkylverbindung geringer wird (F. Troxler und A. Hofmann, Helv. chim. Acta 40, 1957, 1721). Die Arbeit unter den angegebenen Reaktionsbedingungen ist aufwendig, es sind wasserfreie Lösungsmittel erforderlich und unter ungünstigen Bedingungen kann es auch zu Explosionen kommen. Das Reaktionsprodukt muss durch Säulenchromatographie gereinigt werden.The previously known process of N-alkylation of lysergic acids or other compounds of this basic structure is based on the metallization of indole nitrogen with potassium or lithium in liquid ammonia at -50 ° C. and the subsequent introduction of the alkyl group. According to this The alkyl group is only introduced into the 1-stelluna, since the reaction is not particularly selective, especially when the excess of alkyl halide is necessary, it is also accompanied by the substitution of the activated hydrogen at the chiral center 8 with an alkyl group, so that the yield increases N-alkyl compound decreases (F. Troxler and A. Hofmann, Helv. Chim. Acta 40, 1957, 1721). Working under the specified reaction conditions is complex, anhydrous solvents are required and, under unfavorable conditions, explosions can also occur. The reaction product has to be purified by column chromatography.

Das erfindungsgemässe Verfahren zur Herstellung von N-alkylierten 9,10-dihydrolysergsäureestern der allgemeinen Formel I ist dadurch gekennzeichnet, dass die gegebenenfalls veresterten 9,10-Dihydroloysergsäureester der allgemeinen Formel

Figure imgb0002
worin

  • R Wassarstoff oder einen in alkalischem Medium hydrqlisierbaren organischen Rest be- deutet, und
  • X und R2 die unter Formel I angegebene Bedeutung haben,
    mit einer Verbindung der allgemeinen Formel
    Figure imgb0003
    worin
  • R1 die unter Formel I angegebene Bedeutung hat, und
  • Y Halogen oder Sulfat bedeutet,

in Anwesenheit eines Katalysators zur Pha- ,senübertragung, eines,mit Wasser nicht mischbaren inerten organischen Lösungsmittels und einer alkalischen wässerigen Phase umgesetzt werden.The process according to the invention for the preparation of N-alkylated 9,10-dihydrolysergic esters of the general formula I is characterized in that the optionally esterified 9,10-dihydrolysergic esters of the general formula
Figure imgb0002
wherein
  • R is hydrogen or an organic radical which can be hydrolyzed in an alkaline medium, and
  • X and R 2 have the meaning given under formula I,
    with a compound of the general formula
    Figure imgb0003
    wherein
  • R 1 has the meaning given under formula I, and
  • Y is halogen or sulfate,

in the presence of a catalyst for phase transfer, a water-immiscible inert organic solvent and an alkaline aqueous phase.

Nach dem erfindungsgemässen Verfahren wird gleichzeitig in die 1-Stellung der Verbindung der allgemeinen Formel II die Alkylgruppe eingeführt und die Gruppe in der 8-Stellung wird durch dieselbe Alkylgruppe, die in die 1-Lage eingeführt wurde, verestert.In the process according to the invention, the alkyl group is simultaneously introduced into the 1-position of the compound of the general formula II and the group in the 8-position is esterified by the same alkyl group which was introduced into the 1-position.

In der Verbindung der allgemeinen Formel II bedeutet R Wasserstoff oder einen in alkalischem Medium hydrolysierbaren organischen Rest. Deswegen können für das erfindungsgemässe Verfahren auch dee 9,10-Dihydrplysergsäureester verwendet werden, worin R irgend einen organischen Rest bedeutet, der höher als die eingeführte Gruppe R1 ist. Dieser organische Rest R wird durch die intermediäre alkalische Hydrolyse durch eine niedrigere Gruppe R1 ersetzt.In the compound of the general formula II, R denotes hydrogen or an organic radical which can be hydrolyzed in an alkaline medium. For this reason, 9,10-dihydrplysergic acid esters can also be used for the process according to the invention, in which R denotes any organic radical which is higher than the introduced group R 1 is. This organic radical R is replaced by a lower group R 1 by the intermediate alkaline hydrolysis.

Die Verbindungen deralicemeinen Formeln II und III sind bekannt und in der Literatur beschrieben oder können durch an sich bekannte Verfahren hergestellt Werden.The compounds of all my formulas II and III are known and described in the literature or can be prepared by processes known per se.

Die Ausgangsstoffe der Formel II werden durch Verbindungen der allgemeinen Formel III in Anwesenheit einesr Katalysators zur Phasenübertragung alkyliert. Dieser Katalysator ist eine Ammonium- oder Phosphoniumverbindung der allgemeinen Formel Z4QA, worin Z gleiche oder verschiedene Alkyl-, Cycloalkyl-, Aryl-, Arylalkyl- oder Alkylarylgruppen mit 1-16 C-Atomen, Q ein quaternäres Stickstoff- oder Phosphoratom und A ein Anion, wie Chlorid, Bromid, Jodid, Hydrogensulfat, Acetat, Tosylat usw., bedeuten. Als Katalysator zur Phasenübertragung können also z.B. Tetrabutylammoniumbromid, Tetrabutylammoniumhydrogensulfat, Triäthylbenzylammoniumchlorid, Tricaprylylmethylammoniumchlorid, Tetrabutylphosphoniumbromid usw. eingesetzt werden.The starting materials of formula II are alkylated by compounds of general formula III in the presence of a phase transfer catalyst. This catalyst is an ammonium or phosphonium compound of the general formula Z 4 QA, where Z is the same or different alkyl, cycloalkyl, aryl, arylalkyl or alkylaryl groups with 1-16 C atoms, Q is a quaternary nitrogen or phosphorus atom and A is an anion such as chloride, bromide, iodide, hydrogen sulfate, acetate, tosylate, etc. Thus, for example, tetrabutylammonium bromide, tetrabutylammonium hydrogen sulfate, triethylbenzylammonium chloride, tricaprylylmethylammonium chloride, tetrabutylphosphonium bromide, etc. can be used as the catalyst for phase transfer.

Der Katalysator zur Phasenübertragung wird in einer Menge von 0,1 bis 3 Mol auf 1 Mol 9,10-Dihydroloysergsäure eingesetzt. Die Menge des Katalysators in diesen Grenzen beeinflusst sehr die Reaktionsgeschwindigkeit.. Da 9,10-Dihydrolysergsäure und ihre Derivate sehr empfindliche Verbindungen sind, ist ein schneller Reaktionsverlauf erwünscht. Deswegen ist die Verwendung des Katalysators in einer Menge vorteilhaft, die nahe an der angeführten oberen Grenze liegt.The phase transfer catalyst is used in an amount of 0.1 to 3 moles to 1 mole of 9,10-dihydroloysergic acid. The amount of the catalyst within these limits has a great influence on the reaction rate. Since 9,10-dihydrolysergic acid and its derivatives are very sensitive compounds, a rapid course of the reaction is desirable. Therefore, the use of the catalyst in an amount close to the above upper limit is advantageous.

Das mit Wasser nicht mischbare inerte organische Lösungsmittel kann z.B. Benzol, To- luok,Xylol oder ein gesättigter Kohlenwasserstoff, wie Pentan, Hexan, Heptan oder Cyclohexan, sein.The water-immiscible inert organic solvent can e.g. Benzene, Toluok, xylene or a saturated hydrocarbon such as pentane, hexane, heptane or cyclohexane.

Die alkalische wässerige Phase ist eine 20-50 %ige wässerige Alkalihydroxydlösung, z.B. Natriümhydroxydlösung.The alkaline aqueous phase is a 20-50% aqueous alkali hydroxide solution, e.g. Sodium hydroxide solution.

Das erfindungsgemässe Verfahren wird bei Raumtemperatur oder mässig erhöhter Temperatur durchgeführt.The inventive method is carried out at room temperature or moderately elevated temperature.

Die Substitution der 9,10-Dihydrolysergsäuren in der 8-Stellung verläuft schneller als in der 1-Stellung. Deswegen können am Anfang der Reaktion aus dem Reaktionsgemisch der Ester und der N-substituierte Ester isoliert werden. Durch die Weiterführung der Reaktion wird die Konzentration des Esters vermindert, bis sie am Ende der Reaktion vollkommen verschwindet und nur der N-substituierte Ester erhalten wird. Deswegen kann bei der Einführung einer Alkyl- bzw. Alkenyl-und Cycloalkylgruppe in einen 9,10-Dihydrolysergsäurealkyl- bzw. -alkenyl und -cycloalkylester in hoher Ausbeute ein 1-(Alkyl oder Alkenyl oder Cycloalkyl)-9,10-dihydrolysergsäu- realkyl-, -alkenyl- oder -cycloalkylester erhalten werden.The substitution of the 9,10-dihydrolysergic acids in the 8-position is faster than in the 1-position. Therefore, the esters and the N-substituted esters can be isolated from the reaction mixture at the beginning of the reaction. By continuing the reaction, the concentration of the ester is reduced until it completely disappears at the end of the reaction and only the N-substituted ester is obtained. For this reason, when an alkyl or alkenyl and cycloalkyl group is introduced into a 9,10-dihydrolysergic acid alkyl or alkenyl and cycloalkyl ester, a 1- (alkyl or alkenyl or cycloalkyl) -9,10-dihydrolyseric acid alkyl can be obtained in high yield -, -Alkenyl or -cycloalkyl esters can be obtained.

Die Vorteile des erfindungsgemässen Verfahrens gegenüber dem bekannten Verfahren sind gute Selektivität, einfacher und schneller Reaktionsverlauf, wobei die Reaktion leicht kontrolliert wird, Verwendung von üblichen Lösungsmitteln, aus welchen das Wasser nicht entfernt zu werden braucht, vor allem jedoch die Reaktionsbedingungen, die eine fahrlose Arbeit ermöglichen.The advantages of the method according to the invention over the known method are good selectivity, simple and fast reaction course, the reaction being easily controlled, use of conventional solvents from which the water cannot be removed needs, but above all the reaction conditions that make driving possible.

Die erfindungsgemässen Verbindungen sind wichtige Zwischenverbindungen zur Synthese von therapeutisch hochwirksamen Verbindungen mit N-substituierter Gruppen in 1-Stellung. Die weiteren Umsetzungen der Synthese verlaufen vor allem in der Richtung der Reduktion der Estergruppe in der 8-Stellung zu einer primären Alkoholgruppe, auf die dann ein geeigneter Säurerest, z.B. der 5-Bromnicotinsäure, gebunden wird. Deswegen ist die gleichzeitige Einführung der Gruppe R1 in die 1-Stellung und Veresterung der Carboxygruppe in der 8-Stellung, die dadurch für die Reduktion in die Alkoholgruppe zugänglicher wird, sehr vorteilhaft.The compounds according to the invention are important intermediate compounds for the synthesis of therapeutically highly effective compounds with N-substituted groups in the 1-position. The further reactions of the synthesis proceed primarily in the direction of the reduction of the ester group in the 8-position to a primary alcohol group, to which a suitable acid residue, for example 5-bromnicotinic acid, is then bound. Therefore, the simultaneous introduction of the group R 1 in the 1 position and esterification of the carboxy group in the 8 position, which is thereby more accessible for the reduction into the alcohol group, is very advantageous.

Beispiel 1example 1

2,7 g (10 mMol) 9,10-Dihydrolysergsäure und 7 g (20 mMol) Tetrabutylammoniumhydrogensulfat werden in 200 ml 45 %igem Natriumhydroxyd suspendiert. Eine Lösung von 4,2 g (.30 mMol) Methyljodid in 300 ml Benzol wird zugegeben und 1 Stunde intensiv.gerührt. Organische Phase wird dann getrennt und die wässerige Phase in gleicher Weise noch 2 mal mit je 150 ml Benzol, das 2,1 g (15 mMol) Methyljodid enthält, extrahiert. Die Benzolextrakte werden vereinigt, mit Wasser bis zur neutralen Reaktion gewaschen und das Lösungsmittel wird eingedampft. Es werden 2,62 g bzw. 88 % d. Theor. reinen, kristallinen 1-Methyl-9,10-di- hydolysergsäuremethylester mit Schmp. von 116-119°C und einer spezifischen Drehung von

Figure imgb0004
= -61,1° (c = 0,5,Chloroform) erhalten.2.7 g (10 mmol) of 9,10-dihydrolysergic acid and 7 g (20 mmol) of tetrabutylammonium hydrogen sulfate are suspended in 200 ml of 45% sodium hydroxide. A solution of 4.2 g (.30 mmol) of methyl iodide in 300 ml of benzene is added and the mixture is stirred intensively for 1 hour. The organic phase is then separated and the aqueous phase is extracted in the same way twice with 150 ml of benzene, which contains 2.1 g (15 mmol) of methyl iodide. The benzene extracts are combined, washed with water until neutral and the solvent is evaporated. 2.62 g or 88% of theory are used. Theor. pure, crystalline 1-methyl-9,10-dihydrolysergic acid methyl ester with mp. 116-119 ° C and a specific rotation of
Figure imgb0004
= -61.1 ° (c = 0.5, chloroform) obtained.

Beispiel 2Example 2

In ein aus 200 ml 50 %igem Natriumhydroxyd, 7 g (20 mMol) Tetrabutylammoniumhydrogensulfat, 2,8 g (20 mMol) Methyljodid und 300 ml Benzol bestehendes Zweiphasensystem werden unter intensivem Rähren 2,84 g (10 mMol) 9,10-Dihydrolysergsäuremethylester zugegeben. Es wird 30 Minuten gerührt und anschliessend werden die Phasen getrennt. Der wässerigen Phase werden 200 ml Benzol mit 2,1 g (15 mMol) Methyljodid zugegeben und 30 Minuten weitergerührt. Dann werden beide Phasen getrennt und die wässerige Phase noch 2 mal mit je 150 ml Benzol extrahiert. Alle vier Benzolextrakte werden mit Wasser bis zur neutralen Reaktion gewaschen und eingedampft. Es werden 2,7 g bzw. 91 % d. Theor. reinen, kristallinen 1-Methyl-9,10-dihydrolysergsäuremethylester erhalten. Die Verbindung hat die gleichen Eigenschaften wie im Beispiel 1.In a two-phase system consisting of 200 ml of 50% sodium hydroxide, 7 g (20 mmol) of tetrabutylammonium hydrogen sulfate, 2.8 g (20 mmol) of methyl iodide and 300 ml of benzene, 2.84 g (10 mmol) of 9,10-dihydrolysergic acid methyl ester are stirred intensively admitted. The mixture is stirred for 30 minutes and then the phases are separated. 200 ml of benzene with 2.1 g (15 mmol) of methyl iodide are added to the aqueous phase and stirring is continued for 30 minutes. Then both phases are separated and the aqueous phase extracted twice with 150 ml of benzene. All four benzene extracts are washed with water until neutral and evaporated. There are 2.7 g or 91% of theory. Theor. obtained pure, crystalline 1-methyl-9,10-dihydrolysergic acid methyl ester. The compound has the same properties as in Example 1.

Beispiel 3Example 3

2,7 g (10 mMol) 9,10-Dihydrolysergsäure und 6,44 g (20 mMol) Tetrabutylammoniumbromid werden in 200 ml 45 %igem Natriumhydroxyd suspendiert. Es wird eine Lösung von 3,78 g (30 mMol) Dimethyl-sulfat in 300 ml Benzol zugegeben und 1 Stunde intensiv gerührt. Dann wird die organische Phase getrennt und die wässerige Phase in gleicher Weise noch 2 mal mit je 150 ml Benzol und 2,1 g (15 mMol) Methyljodid extrahiert. Die Benzolextrakte werden vereinigt, mit Wasser bis zur neu- tralen Reaktion gewaschen und in Vakuum eingedampft. Es werden 2,36 g bzw. 82,6 % d. Theor. reinen, kristallinen 1-Methyl-9,10-dihydroly- sergsäuremethylester erhalten. Die Verbindung hat die gleichen Eigenschaften wie im Beispiel 1.2.7 g (10 mmol) of 9,10-dihydrolysergic acid and 6.44 g (20 mmol) of tetrabutylammonium bromide are suspended in 200 ml of 45% sodium hydroxide. A solution of 3.78 g (30 mmol) of dimethyl sulfate in 300 ml of benzene is added and the mixture is stirred intensively for 1 hour. The organic phase is then separated and the aqueous phase is extracted in the same way twice with 150 ml of benzene and 2.1 g (15 mmol) of methyl iodide. The benzene extracts are combined, washed with water until neutral and evaporated in vacuo. 2.36 g or 82.6% of theory. Theor. obtained pure, crystalline 1-methyl-9,10-dihydrolysergic acid methyl ester. The compound has the same properties as in Example 1.

Beispiel 4Example 4

2,7 g (10 mMol) 9,10-Dihydrolysergsäure und 7 g (20 mMol) Tetrabutylammoniumhydrogensul- fat werden in 200 ml 45 %igem Natriumhydroxyd suspendiert und eine Lösung von 4,62 g (30 mMol) Diäthylsulfat in 300 ml Toluol wird zugegeben. Bei Raumtemperatur wird 8 Stunden intensiv gerührt. Dann wird die organische Phase getrennt und die wässerige Phase in gleicher Weise noch 4 Stunden mit 300 ml Toluol und 1,54 g (10 mMol) Diäthylsulfat extrahiert. Die Toluolextrakte werden vereinigt, mit Wasser bis zur neutralen Reaktion gewaschen und in Vakuum eingedampft. Es werden 2,15 g bzw. 68,7 % d. Theor. reinen, kristallinen 1-Äthyl-9,10-dihydrolysergsäureäthyl- ester mit einem Schmp. von 80-82°C und spezifischer Drehung

Figure imgb0005
= -70,6° (c = 0,5, Chloroform) erhalten.2.7 g (10 mmol) of 9,10-dihydrolysergic acid and 7 g (20 mmol) of tetrabutylammonium hydrogen sulfate are suspended in 200 ml of 45% sodium hydroxide and a solution of 4.62 g (30 mmol) of diethyl sulfate in 300 ml of toluene admitted. The mixture is stirred vigorously at room temperature for 8 hours. The organic phase is then separated and the aqueous phase is extracted in the same way for 4 hours with 300 ml of toluene and 1.54 g (10 mmol) of diethyl sulfate. The toluene extracts are combined, washed with water until neutral and evaporated in vacuo. There are 2.15 g or 68.7% of theory. Theor. pure, crystalline 1-ethyl-9,10-dihydrolysergic acid ethyl ester with a melting point of 80-82 ° C and specific rotation
Figure imgb0005
= -70.6 ° (c = 0.5, chloroform) obtained.

Beispiel 5Example 5

2,7 g (10 mMol) 9,10-Dihydrolysergsäure und 7 g ,(20 mMol) Tetrabutylammoniumhydrogensulfat werden in 200 ml 45 %igem Natriumhydroxyd suspendiert, eine Lösung von 4,85 g (40 mMol) Allylbromid in 300 ml Benzol wird zugegeben und 2 Stunden-intensiv gerührt. Dann werden die Phasen getrennt und die wässerige Phase in gleicher Weise noch 2 mal mit je 200 ml Benzol und 2,42 g (20 mMol) Allylbromid extrahiert. Die Benzolextrakte werden vereinigt, mit Wasser bis zur neutralen Reaktion gewaschen und in Vakuum eingedampft. Es werden 2,3 g bzw. 66 % d. Theor. 1-Allyl-9,10-dihydrolysergsäureallylester in der Form eines farblosen Harzes mit spezifischer Drehung von

Figure imgb0006
= -69,9° (c = 0,5, Chloroform) erhalten.2.7 g (10 mmol) 9,10-dihydrolysergic acid and 7 g, (20 mmol) tetrabutylammonium hydrogen sulfate are suspended in 200 ml 45% sodium hydroxide, a solution of 4.85 g (40 mmol) allyl bromide in 300 ml benzene is added and stirred intensively for 2 hours. The phases are then separated and the aqueous phase is extracted in the same way twice with 200 ml of benzene and 2.42 g (20 mmol) of allyl bromide. The benzene extracts are combined, washed with water until neutral and evaporated in vacuo. 2.3 g or 66% of theory are used. Theor. 1-Allyl-9,10-dihydrolysergic acid allyl ester in the form of a colorless resin with specific rotation of
Figure imgb0006
= -69.9 ° (c = 0.5, chloroform) obtained.

Figure imgb0007
Figure imgb0007

Beispiel 7Example 7

Ein Gemisch aus 4,5 g (13,22 mMol) 10α-Methoxy-lumilysergsäuremethylester, 8,67 g (26,44 mMol) Tetrabutylammoniumhydrogensulfat, 200 ml 45 %igem Natriumhydroxyd, 300 ml Toluol und 3,33 g (26,44 mMol) Dimethylsulfat wird 20 Minuten bei 30°C intensiv gerührt. Dann wird die Toluolphase von der Wasserphase getrennt und die Wasserphase-noch 3 mal mit je 200 ml Toluol und 1,66 g (13,22 mMol) Dimethylsulfat extrahiert, wobei jeweils 20 Minuten intensiv bei 30°C gerührt wird. Die vereinigten Toluolextrakte werden mit Wasser gevaschen und in Vakuum eingedampft. Es werden 3,8 g 1-Methyl-10α-methoxy-

Figure imgb0008
in der Form eines farblosen Harzes mit der spezifischen Drehung
Figure imgb0009
= -8.7° (c = 0,5,Chloroform) erhalten.A mixture of 4.5 g (13.22 mmol) of 10α-methoxy-lumilysergic acid methyl ester, 8.67 g (26.44 mmol) of tetrabutylammonium hydrogen sulfate, 200 ml of 45% sodium hydroxide, 300 ml of toluene and 3.33 g (26.44 mmol) of dimethyl sulfate is stirred intensively at 30 ° C. for 20 minutes. Then, the toluene phase is separated from the water phase and the water phase was extracted 3 times with 200 ml of toluene and 1.66 g (13.22 mmol) of dimethyl sulfate, in each case 20 minutes intensively stirred at 30 ° C. The combined toluene extracts are washed with water and evaporated in vacuo. 3.8 g of 1-methyl-10α-methoxy
Figure imgb0008
in the form of a colorless resin with the specific rotation
Figure imgb0009
= -8.7 ° (c = 0.5, chloroform) obtained.

In eine Suspension von 40 ml 45 %igem Natriumhydroxid, 4,87 g (14,3 mMol) Tetrabutylammoniumhydrogensulfat, 250 ml Benzol und 3 g (21,5 mMol) Methyljodid werden unter invensivem Rühren bei 35°C 2,6 g (7,16 mMol) 2-Brom-9,10-dihydrolysergsäuremethylester in 65 ml Benzol zugegeben. Die Lösung wird 30 Minuten gerührt und anschliessehd wird die organische Phase von der wässerigen Phase getrennt. Die wässerige Phase wird hoch 2 mal mit je 150 ml Benzol und 1,5 g (10,7 mMol) Methyljodid extrahiert. Die vereinigten Benzolextrakte werden mit Wasser gewaschen und in Vakuum eingedampft. Der Trockenrückstand wird aus Methanol kristallisiert. Es werden 2,42 g bzw. 90 % d. Theor. kristallinen 1-Methyl-2-brom-9,10-dihydrolysergsäuremethyl- ester mit Schmp. 167-168°C und der spezifischen Drehung

Figure imgb0010
= -94,2° (c = 0,5,Methanol) erhalten.In a suspension of 40 ml 45% sodium hydroxide, 4.87 g (14.3 mmol) tetrabutylammonium Hydrogen sulfate, 250 ml of benzene and 3 g (21.5 mmol) of methyl iodide are added while stirring invensively at 35 ° C. 2.6 g (7.16 mmol) of 2-bromo-9,10-dihydrolysergic acid methyl ester in 65 ml of benzene. The solution is stirred for 30 minutes and then the organic phase is separated from the aqueous phase. The aqueous phase is extracted twice with 150 ml of benzene and 1.5 g (10.7 mmol) of methyl iodide. The combined benzene extracts are washed with water and evaporated in vacuo. The dry residue is crystallized from methanol. There are 2.42 g or 90% of theory. Theor. crystalline 1-methyl-2-bromo-9,10-dihydrolysergic acid methyl ester with mp. 167-168 ° C and the specific rotation
Figure imgb0010
= -94.2 ° (c = 0.5, methanol) obtained.

Beispiel 9Example 9

In eine Suspension aus 80 ml 45 %igem Natriumhydroxyd, 3,5 g (10 mMol) Tetrabutylammoniumhydrogensulfat, 200 ml Cyclohexan und 3,51 g (22,5 mMol) Äthyljodid werden unter Rühren 1,45 g (5mMol) 9,10-Dihydrolysergsäureäthyl- ester zugegeben. Es wird 18 Stunden intensiv bei 60°C gerührt. Nach der Trennung beider Phasen wird die wässerige Phase noch einmal mit 150 ml Cyclohexan und 1,56 g (10 mMol) Äthyljodid extra- hiert. Die Cyclohexanfraktionen werden vereinigt, mit Wasser gewaschen und eingedampft. Es werden 1,22 g bzw. 80% d. Theor. 1-Äthyl-9,10-dihydroly- sergsäüreäthylester mit einem Schmp. von 80-83°C und einer spezifischen Drehung

Figure imgb0011
= -70° (c = 0,5, Chloroform) erhalten.In a suspension of 80 ml of 45% sodium hydroxide, 3.5 g (10 mmol) of tetrabutylammonium hydrogen sulfate, 200 ml of cyclohexane and 3.51 g (22.5 mmol) of ethyl iodide, 1.45 g (5 mmol) of 9.10- Dihydrolysergic acid ethyl ester added. The mixture is stirred intensively at 60 ° C. for 18 hours. After the two phases have been separated, the aqueous phase is extracted once more with 150 ml of cyclohexane and 1.56 g (10 mmol) of ethyl iodide. The cyclohexane fractions are combined, washed with water and evaporated. There will be 1.22 g or 80% of theory. Theor. Ethyl 1-ethyl-9,10-dihydrolysate with a melting point of 80-83 ° C and a specific rotation
Figure imgb0011
= -7 0 ° (c = 0.5, chloroform) obtained.

Beispiel 10Example 10

In ein Zweiphasensysten bestehend aus 200 ml 45 %igem Natriumhydroxyd, 7 g (20 mMol) Tetrabutylammoniumhydrogensulfat, 200 ml Toluol und 2,52 g (20 mMol) Dimethylsulfat, wird unter intensiver Rühren eine Lösung von 3,16 g (10 mMol) 9,10-Dihydrolysergsäure-2'-fluoräthylester in 100 ml Toluol zugegeben und 2 Stunden gerührt. Der Toluolextrakt wird von der wässerigen Lösung getrennt und dann wird die wässerige Lösung noch 2 mal mit je 200 ml Toluol und 0,63 g (5 mMol) Dimethylsulfat extrahiert. Die vereinigten Toluolextrakte werden mit Wasser gewaschen und in Väkuum bis zur Trockne eingedampft. Es werden 2,14 g bzw. 71,8 % d. Theor. kristallinen 1-Methyl-9,10-di- hydrolysergsäuremethylester erhalten. Die Verbindung hat die im Beispiel 1 angegebenen Eigenschaften.In a two-phase system consisting of 200 ml of 45% sodium hydroxide, 7 g (20 mmol) of tetrabutylammonium hydrogen sulfate, 200 ml of toluene and 2.52 g (20 mmol) of dimethyl sulfate, a solution of 3.16 g (10 mmol) 9 is stirred , 10-Dihydrolysergic acid 2'-fluoroethyl ester in 100 ml of toluene and stirred for 2 hours. The toluene extract is separated from the aqueous solution and then the aqueous solution is extracted twice with 200 ml of toluene and 0.63 g (5 mmol) of dimethyl sulfate. The combined toluene extracts are washed with water and evaporated to dryness in vacuo. There are 2.14 g or 71.8% of theory. Theor. obtained crystalline 1-methyl-9,10-dihydrolysergic acid methyl ester. The compound has the properties given in Example 1.

Claims (2)

1. N-substituierte 9,10-Dihydrolysergsäureester der allgemeinen Formel
Figure imgb0012
worin R1 Alkylreste mit 1-5 C-Atomen, Alkenylreste mit 2-5 C-Atomen oder Cycloalkylreste mit 3-5 C-Atomen, R2 Wasserstoff oder Alkoxyreste mit 1-3 C-Atomen und X Wasserstoff oder Halogen bedeuten, wobei die Verbindung, worin R1 Methyl- oder Äthylrest und R2 und X Wasserstoff bedeuten, sowie die Verbindungen, worin R1 einen Methylrest, R2 einen Methoxyrest und X Wasserstoff bedeuten, ausgenommen sind.
1. N-substituted 9,10-dihydrolysergic acid esters of the general formula
Figure imgb0012
wherein R 1 alkyl residues with 1-5 C atoms, alkenyl residues with 2-5 C atoms or cycloalkyl residues with 3-5 C atoms, R 2 is hydrogen or alkoxy radicals with 1-3 C atoms and X is hydrogen or halogen, except for the compound in which R 1 is methyl or ethyl and R 2 and X are hydrogen, and the compounds in which R 1 is methyl, R 2 is methoxy and X is hydrogen.
2. Verfahren zur Herstellung von N-substituierten 9,10-Dihydrolysergsäureestern der allgemeinen Formel
Figure imgb0013
worin R1 Alkylreste. mit 1-5 C-Atomen, Alkenylreste mit 2-5 C-Atomen oder Cycloalkylreste mit 3-5 C-Atomen, R2 Wasserstoff oder Alkoxyrestemit 1-3 C-Atomen und X Wasserstoff oder Halogen bedeuten, dadurch gekennzeichnet, dass die gegebenenfalls veresterten 9,10-Dihydrolysergsäuren der allgemeinen Formel
Figure imgb0014
worin
R Wasserstoff oder einen in alkalischem Medium hydrolysierbaren organischen Rest be- deutet und X und R2 die unter Formel I angegebene 3e-deutung haben,
mit einer Verbindung der allgemeinen Formel
Figure imgb0015
worin
R1 die unter Formel I angegebene Bedeutung hat und Y Halogen oder Sulfat bedeutet,
in Anwesenheit eines Katalysators zur Phasenübertragung, eines mit Wasser nicht mischbaren inerten organischen Lösungsmittels und einer alkalischen wässerigen Phase umgesetzt werden.
2. Process for the preparation of N-substituted 9,10-dihydrolysergic acid esters of the general formula
Figure imgb0013
wherein R 1 alkyl radicals. with 1-5 C atoms, alkenyl residues with 2-5 C atoms or cycloalkyl residues with 3-5 C atoms, R 2 is hydrogen or alkoxy radicals with 1-3 C atoms and X is hydrogen or halogen, characterized in that the optionally esterified 9,10-dihydrolysergic acids of the general formula
Figure imgb0014
wherein
R is hydrogen or an organic radical which can be hydrolyzed in an alkaline medium, and X and R 2 have the 3e interpretation given under formula I,
with a compound of the general formula
Figure imgb0015
wherein
R 1 has the meaning given under formula I and Y is halogen or sulfate,
in the presence of a phase transfer catalyst, a water-immiscible inert organic solvent and an alkaline aqueous phase.
EP78100419A 1977-07-21 1978-07-18 N-substituted 9,10-dihydrolysergic acid esters and a method for their preparation Expired EP0000533B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
YU1819/77 1977-07-21
YU1819/77A YU40004B (en) 1977-07-21 1977-07-21 Praocess for preparing n-substituted esters of 9,10-dihydrlysergic acid

Publications (2)

Publication Number Publication Date
EP0000533A1 true EP0000533A1 (en) 1979-02-07
EP0000533B1 EP0000533B1 (en) 1981-08-05

Family

ID=25555705

Family Applications (1)

Application Number Title Priority Date Filing Date
EP78100419A Expired EP0000533B1 (en) 1977-07-21 1978-07-18 N-substituted 9,10-dihydrolysergic acid esters and a method for their preparation

Country Status (11)

Country Link
US (1) US4230859A (en)
EP (1) EP0000533B1 (en)
JP (1) JPS5436296A (en)
AT (1) AT363195B (en)
CS (1) CS216231B2 (en)
DE (1) DE2860896D1 (en)
ES (1) ES471716A1 (en)
FI (1) FI64369C (en)
PT (1) PT68278A (en)
SU (1) SU784775A3 (en)
YU (1) YU40004B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0208622A1 (en) * 1985-07-11 1987-01-14 Rhone-Poulenc Sante Process for the preparation of N-methyl derivatives of ergoline
FR2584721A1 (en) * 1985-07-11 1987-01-16 Rhone Poulenc Sante PROCESS FOR PREPARING N-METHYL DERIVATIVES OF METHYL DIHYDROLYSERGATE OR METHYL METHOXYLUMILYSERGATE
EP0218433A1 (en) * 1985-10-01 1987-04-15 Eli Lilly And Company Selective method for blocking 5HT2 receptors
EP0219256A1 (en) * 1985-10-01 1987-04-22 Eli Lilly And Company N-Alkylation of dihydrolysergic acid
EP0291270A3 (en) * 1987-05-11 1989-12-06 Eli Lilly And Company Improvements in or relating to ergoline derivatives

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563461A (en) * 1983-03-10 1986-01-07 Eli Lilly And Company Selective method for blocking 5HT2 receptors
US4772709A (en) * 1985-10-01 1988-09-20 Eli Lilly And Company Process of making ketoalkanol esters of dihydrolysergic acid
US4845224A (en) * 1985-10-01 1989-07-04 Eli Lilly And Company Cycloalkanol esters of dihydrolysergic acid having peripheral serotonin antagonist properties
US4810710A (en) * 1985-10-01 1989-03-07 Eli Lilly And Company 4-hydroxycyclohexyl 1-isopropyl-9,10-dihydro-lysergate for the treatment of migraine
US4714704A (en) * 1985-10-01 1987-12-22 Eli Lilly And Company Alkoxy cycloalkanol esters of dihydrolysergic acid useful as 5HT receptor antagonists
US4847261A (en) * 1985-10-01 1989-07-11 Eli Lilly And Company Alkoxy cycloalkanol esters of dihydrolysergic acid having peripheral serotonin antagonists properties
US4713385A (en) * 1985-10-01 1987-12-15 Eli Lilly And Company Alkoxy and dialkoxyalkyl esters of dihydrolysergic acid and related compounds useful as 5HT receptor antagonists
US4762842A (en) * 1985-10-01 1988-08-09 Eli Lilly And Company Selective method for blocking 5HT2 receptors
US4968802A (en) * 1985-10-01 1990-11-06 Eli Lilly And Company Process of making alkoxy cycloalkanol esters of dihydrolysergic acid
US4939258A (en) * 1985-10-01 1990-07-03 Eli Lilly And Company Cycloalkanol esters of dihydrolysergic acid
US4820713A (en) * 1985-10-01 1989-04-11 Eli Lilly And Company Ketoalkanol esters of dihydrolysergic acid useful as 5HT receptor antagonists
US4683236A (en) * 1985-10-01 1987-07-28 Eli Lilly And Company Cycloalkanol esters of dihydrolysergic acid useful as 5Ht2 receptor antagonists
US4906639A (en) * 1985-10-01 1990-03-06 Eli Lilly And Company Cycloalkanol esters of dihydrolysergic acid
US4683237A (en) * 1985-12-20 1987-07-28 Eli Lilly And Company Fluoroalkyl esters of dihydrolysergic acid useful as 5HT2 receptor antagonists
US4704396A (en) * 1985-12-20 1987-11-03 Eli Lilly And Company Phenacyl esters of 1-substituted-6-(substituted and unsubstituted) dihydrolysergic acids useful as 5HT receptor antagonists
US4704395A (en) * 1985-12-20 1987-11-03 Eli Lilly And Company Cyclic ether esters of 2-substituted-6-(substituted and unsubstituted) dihydrolysergic acid useful as 5HT receptor antagonists
US4835159A (en) * 1987-05-11 1989-05-30 Eli Lilly And Company Ergoline esters useful as serotonin antagonists
US4981859A (en) * 1987-06-15 1991-01-01 Cycloalkylamides of (8 beta )-1-alkyl-6-(substituted)ergolines
US4931447A (en) * 1987-06-15 1990-06-05 Eli Lilly And Company Cycloalkylamides of (8β)-1-alkyl-6-(substituted) ergolines
JPH01106511U (en) * 1988-01-02 1989-07-18
JPH02125915U (en) * 1989-03-29 1990-10-17

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1175276A (en) * 1956-05-18 1959-03-23 Sandoz Ag New derivatives of the lysergic acid series and their preparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA631701A (en) * 1961-11-28 Sandoz A.G. Compounds of the lysergic acid series alkylated at the indol nitrogen atom
CH344731A (en) * 1956-05-18 1960-02-29 Sandoz Ag Process for the production of new derivatives of the lysergic acid series alkylated on the indole nitrogen
US3228943A (en) * 1962-06-11 1966-01-11 Lumilysergol derivatives
US3232942A (en) * 1964-06-02 1966-02-01 Sandoz Ltd 1-substituted (+)-lysergol
GB1298277A (en) * 1969-04-18 1972-11-29 Sandoz Ltd Preparation of ergot peptide alkaloids
US3879554A (en) * 1970-03-20 1975-04-22 Farmaceutici Italia Use of 1,6-dimethyl-8-{62 -(5-bromonicotinoyloxymethyl)-10 {60 -methoxyergoline in treating cerebral and peripheral metabolic vascular disorders
NL159384B (en) * 1971-03-13 1979-02-15 Farmaceutici Italia PROCEDURE FOR PREPARING A MEDICINAL PRODUCT WITH AN ADRENOLYTIC ACTIVITY, AS WELL AS A PROCEDURE FOR PREPARING AN ESTER OF 1-METHYL-10-METHOXYLUMILYSERGOL.
DE2330912C3 (en) * 1972-06-22 1979-01-11 Societa Farmaceutici Italia S.P.A., Mailand (Italien) Process for the preparation of bromergoline compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1175276A (en) * 1956-05-18 1959-03-23 Sandoz Ag New derivatives of the lysergic acid series and their preparation

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0208622A1 (en) * 1985-07-11 1987-01-14 Rhone-Poulenc Sante Process for the preparation of N-methyl derivatives of ergoline
FR2584721A1 (en) * 1985-07-11 1987-01-16 Rhone Poulenc Sante PROCESS FOR PREPARING N-METHYL DERIVATIVES OF METHYL DIHYDROLYSERGATE OR METHYL METHOXYLUMILYSERGATE
FR2584720A1 (en) * 1985-07-11 1987-01-16 Rhone Poulenc Sante PROCESS FOR THE PREPARATION OF N-METHYL DERIVATIVES OF ERGOLINE
EP0211728A1 (en) * 1985-07-11 1987-02-25 Rhone-Poulenc Sante Process for the preparation of the N-methyl derivatives of the methyl ester of dihydrolysergic acid or of the methyl ester of methoxylumilysergic acid
US4739061A (en) * 1985-07-11 1988-04-19 Rhone-Poulenc Sante Process for preparing n-methyl derivatives of methyl dihydrolysergate and methyl methoxylumilysergate
US4754037A (en) * 1985-07-11 1988-06-28 Rhone-Poulenc Sante Process for preparing N-methyl derivatives of ergoline
EP0218433A1 (en) * 1985-10-01 1987-04-15 Eli Lilly And Company Selective method for blocking 5HT2 receptors
EP0219256A1 (en) * 1985-10-01 1987-04-22 Eli Lilly And Company N-Alkylation of dihydrolysergic acid
EP0291270A3 (en) * 1987-05-11 1989-12-06 Eli Lilly And Company Improvements in or relating to ergoline derivatives

Also Published As

Publication number Publication date
DE2860896D1 (en) 1981-11-05
ATA490078A (en) 1980-12-15
FI64369C (en) 1983-11-10
US4230859A (en) 1980-10-28
CS216231B2 (en) 1982-10-29
SU784775A3 (en) 1980-11-30
AT363195B (en) 1981-07-10
EP0000533B1 (en) 1981-08-05
PT68278A (en) 1978-08-01
JPS5436296A (en) 1979-03-16
YU181977A (en) 1983-01-21
FI782081A7 (en) 1979-01-22
FI64369B (en) 1983-07-29
YU40004B (en) 1985-06-30
JPS5648512B2 (en) 1981-11-16
ES471716A1 (en) 1979-10-01

Similar Documents

Publication Publication Date Title
EP0000533B1 (en) N-substituted 9,10-dihydrolysergic acid esters and a method for their preparation
CH617442A5 (en)
EP0086324B1 (en) Process for preparing ascorbic acid
DE2661094C2 (en)
DE69707860T2 (en) METHOD FOR PRODUCING TETRAHYDROINDOLIZINES
DE2318001A1 (en) NEW DIENIC SULPHONES
DD201592A5 (en) PROCESS FOR THE PREPARATION OF NEW INDOLOCHINOLISINESTER DERIVATIVES
DE2752533B2 (en) Process for the preparation of 10 a -Methoxydttiydrolysergol-S&#39;-bromnocotinsäureester
CH642658A5 (en) RACEMIC OR OPTICALLY ACTIVE OXIMINO-E-HOMO-EBURNAN DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF.
DE2354327C3 (en) 2-Amino-1,23&gt; 4-tetrahydronaphthalene derivatives, processes for their preparation and processes for the preparation of 6,7-benzomorphans starting from those
DE2521088A1 (en) DITERPENIC ANILIDES AND METHOD FOR MANUFACTURING THEREOF
DE2065698A1 (en) PROCESS FOR THE PREPARATION OF 2ISOPROPYL-6-METHYL-4 (3H) -PYRIMIDONE
DE1643014C3 (en) Process for the production of cardenolides
EP0003484B1 (en) Process for the preparation of chromane derivatives
DE2256866C3 (en) Process for the preparation of 17 alpha- or 17beta-hydroxy compounds of the 20-ketopregnane or -17alpha-pregnane series
DE2331044A1 (en) DIPHENYLMETHANE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION
DE2516544A1 (en) PROCESS FOR PRODUCING TRANS-DECALIN DERIVATIVES
DE2533899C3 (en) Process for the preparation of steryl-β-glucoside esters
DE2628469B2 (en) Process for the preparation of γ-amino alcohols
DE2705874C2 (en) Process for the preparation of phloroglucinol and phloroglucinol derivatives
DE2243112C3 (en) Process for the preparation of substituted aromatic compounds nitrated in the side chain
DE2517770C3 (en) Process for the production of
DE68915213T2 (en) Process for the preparation of vitamin A or its carboxylic acid esters.
DE1643587C3 (en) Process for the production of 13 alkylgon 5 (10&gt; en 3 beta oils
DE2238586C3 (en) Process for the production of A16-17 ethinyl steroids

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): BE CH DE FR GB SE

17P Request for examination filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): BE CH DE FR GB SE

REF Corresponds to:

Ref document number: 2860896

Country of ref document: DE

Date of ref document: 19811105

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19840630

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19840710

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19840719

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19840927

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19840930

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19860719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Effective date: 19860731

Ref country code: BE

Effective date: 19860731

BERE Be: lapsed

Owner name: LEK TOVARNA FARMACEVTSKIH IN KEMICNIH IZDELKOV N.

Effective date: 19860731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19870331

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19870401

GBPC Gb: european patent ceased through non-payment of renewal fee
REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19881117

EUG Se: european patent has lapsed

Ref document number: 78100419.7

Effective date: 19870518

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT